Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...
Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback